The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease
201试验：一项安慰剂对照的随机II期研究，旨在评估c-Abl激酶抑制剂risvodetinib在未经治疗的帕金森病患者中的安全性和耐受性
期刊:Nature Aging
影响因子:19.4
doi:10.1038/s43587-026-01084-4
Werner, M H; McGarry, A; Meyer, C; Mancino, E; Klint, C; Pellecchia, J; Kieburtz, K; Levine, T; Bellaire, B; Gibbons, C; Freeman, R; Ellenbogen, A; Klos, K; Ospina, M; Hauser, R A; Shannon, K; Asaad, H; Park, A; McAllister, P; Isaacson, S H; LeDoux, M S; Dhall, R; Shpiner, D; Charles, P; Agarwal, P; Peckham, E; Mazzeo, P; Davis, M; Pahwa, R; Brodsky, M; Lew, M; Purino, L; Mantri, S; Parashos, S; Justiz, W; Chachar, M; Robottom, B; Budman, E; Blindauer, K; Bellows, S; Goudreau, J; Steen, S; Olanow, C W
